Assignee
ONCONOVA THERAPEUTICS INC
US·10 granted patents·10 pending applications·29 citations·filing 2002–2024
Top patents by PatentIndex Score
20 records- 0181US11382877B2Formulation of (E)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailabilityONCONOVA THERAPEUTICS INC·Filed 2018·Granted Jul 12, 2022·1 cites·14 claims
- 0280US6579988B2Processes for the preparation of 1,5-diarylpyrazolesONCONOVA THERAPEUTICS INC·Filed 2002·Granted Jun 17, 2003·8 cites·11 claims
- 0379US10098862B1Formulations with enhanced stability and bioavailability for administration of (E)-2,6-dialkoxystyryl 4-substituted benzylsulfonesONCONOVA THERAPEUTICS INC·Filed 2017·Granted Oct 16, 2018·2 cites·33 claims
- 0477US7161031B2Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disordersONCONOVA THERAPEUTICS INC·Filed 2003·Granted Jan 9, 2007·11 cites·77 claims
- 0570US6706927B2Alkyne ketonesONCONOVA THERAPEUTICS INC·Filed 2003·Granted Mar 16, 2004·3 cites·2 claims
- 0666US6906196B2Processes for the preparation of 1,5-diaryl-3-substituted-pyrazolesONCONOVA THERAPEUTICS INC·Filed 2002·Granted Jun 14, 2005·2 cites·9 claims
- 0763US6809204B2Processes for the preparation of substituted isoxazoles and 2-isoxazolinesONCONOVA THERAPEUTICS INC·Filed 2002·Granted Oct 26, 2004·1 cites·25 claims
- 0860US10576050B2Methods and compositions for treatment of cancerONCONOVA THERAPEUTICS INC·Filed 2013·Granted Mar 3, 2020·1 cites·10 claims
- 0955US2009247624A1Formulations of radioprotective alpha beta unsaturated aryl sulfonesONCONOVA THERAPEUTICS INC·Filed 2007·Application pending·0 cites
- 1055US2011028504A1Formulation of radioprotective alpha beta unsaturated aryl sulfonesONCONOVA THERAPEUTICS INC·Filed 2006·Application pending·0 cites
- 1154US7094903B2Processes for the preparation of substituted isoxazoles and 2-isoxazolinesONCONOVA THERAPEUTICS INC·Filed 2004·Granted Aug 22, 2006·0 cites·22 claims
- 1253US2011250184A1Methods for determining efficacy of a therapeutic regimen against deleterious effects of cytotoxic agents in humanONCONOVA THERAPEUTICS INC·Filed 2009·Application pending·0 cites
- 1350US2024366610A1Methods and compositions for treating cancerONCONOVA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1450US2024374600A1Methods and compositions for treating cancerONCONOVA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1550US2024374601A1Methods and compositions for treating cancerONCONOVA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1649US2024299326A1Methods and compositions for treating cancerONCONOVA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1749US2024269099A1Methods and compositions for treating cancerONCONOVA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1847US9713597B2Stable aqueous formulation of (E)-4-carboxystyryl-4-chlorobenzyl sulfoneONCONOVA THERAPEUTICS INC·Filed 2015·Granted Jul 25, 2017·0 cites·9 claims
- 1944US2022002293A18-cyclopentyl-7-oxo-2-(4-piperazin-1-yl-phenylamino)-7, 8-dihydro-pyrido [2,3-d]pyrimidine-6-carbonitrile and uses thereof in treating proliferative disordersONCONOVA THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2040US2016102363A1Methods and compositions for predicting therapeutic efficacy of kinase inhibitors in patients with myelodysplastic syndrome or related disordersONCONOVA THERAPEUTICS INC·Filed 2014·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →